

P&T Motion History Overactive Bladder

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
darifenacin fesoterodine fumarate flavoxate HCL mirabegron oxybutynin chloride solifenacin tolterodine tartrate trospium chloride	After considering the evidence of safety, efficacy and special populations for the treatment of over active bladder, I move that darifenacin, fesoterodine fumarate, flavoxate, mirabegron, oxybutynin-gel/patch/tab, solifenacin, tolterodine and trospium are safe and efficacious. These drugs can be subject to therapeutic interchange in the Washington preferred drug list, immediate release formulations cannot be interchanged for a once daily formulations and vice versa. A once daily formulation must be included as a preferred drug on the Washington preferred drug list. Motion: Wiser 2 nd : Rowe	April 20, 2016	Yes Figuroa Harvey	Yes Klingel Johnson	Passed Unanimous
		June 17, 2015	Yes Wiser Sanderson	Yes Rowe Harvey	Passed Unanimous